Autobahn Therapeutics Advances to Phase II for Mood Disorders with $100M Financing

1. Autobahn Therapeutics: The company is moving forward with its clinical trials for mood disorders, entering Phase II.
2. Financing: Autobahn has secured $100 million in financing from prominent pharmaceutical companies, including Bristol Myers Squibb ($BMY), Biogen ($BIIB), and Pfizer ($PFE).
3. Mood Disorders: The company's focus is on developing treatments for mood disorders, which includes depression.
4. Neuropsychiatry: Autobahn is part of the growing trend of neuropsychiatry startups, which are actively involved in M&A deals and private/public financings.
5. Clinical Trials: The Phase II clinical trials mark a significant milestone in Autobahn's development process for its mood disorder treatments.